Knight Therapeutics (KHTRF) Expected to Release Quarterly Earnings on Thursday

Knight Therapeutics (OTCMKTS:KHTRF) will likely be announcing its results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of $0.01 per share and revenue of $88.9650 million for the quarter.

Knight Therapeutics Stock Performance

Shares of Knight Therapeutics stock opened at $7.05 on Thursday. The business has a 50-day moving average of $6.64 and a two-hundred day moving average of $5.53. Knight Therapeutics has a 1 year low of $4.07 and a 1 year high of $7.40.

Wall Street Analysts Forecast Growth

Separately, Royal Bank Of Canada reiterated an “outperform” rating on shares of Knight Therapeutics in a research report on Friday, May 8th. One analyst has rated the stock with a Buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy”.

Knight Therapeutics Company Profile

Knight Therapeutics Inc (OTCMKTS:KHTRF) is a specialty pharmaceutical company headquartered in Montreal, Canada, focused on acquiring, in-licensing and commercializing innovative branded products for the Canadian and Latin American markets. The company secures exclusive marketing and distribution rights to medicines across multiple therapeutic areas, including ophthalmology, pain management, hematology and women’s health. Its portfolio features both prescription pharmaceuticals and specialty products that address unmet patient needs through targeted treatments.

Operating primarily in Canada, Mexico and select Latin American countries, Knight has established strategic alliances with global pharmaceutical firms to introduce novel therapies at various stages of development.